Namzaric Capsule
Product Images NDC 0456-1228

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Namzaric (NDC 0456-1228). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Allergan, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Namzaric 01

Chemical structure diagram of the active ingredient shown, including functional groups such as an amine and methyl groups, along with a hydrochloride moiety. The diagram displays a bicyclic framework with specified substituents.*

FDA Label Image

Namzaric 02

Chemical structure of Namzaric showing the molecular arrangement of its active components, including aromatic rings, piperazine ring, and methoxy groups, along with a hydrochloride component.*

FDA Label Image

Namzaric 03

A line graph depicting the mean change from baseline in SIB score over 24 weeks of treatment. Two lines compare Memantine HCl ER 28 mg/AChEI and Placebo/AChEI groups, showing clinical improvement or decline with error bars for SEM at various time points over weeks.*

FDA Label Image

Namzaric 04

A line chart showing the cumulative percentage of patients on the y-axis and SIB change from baseline on the x-axis, comparing Memantine HCl ER 28 mg/AChEI treatment versus placebo/AChEI. The chart illustrates two curves representing patient response distributions for the treatment and placebo groups.*

FDA Label Image

Namzaric 05

This line graph compares the CIBIC-Plus scores over 24 weeks of treatment for Namzaric (Memantine HCl ER 28 mg/AChEI) versus placebo with AChEI. It shows mean scores with error bars, indicating clinical improvement and decline zones, plotted against weeks of treatment from 0 to 24.*

FDA Label Image

Namzaric 06

A bar chart comparing percentages of patients across CIBIC-Plus Rating categories between Memantine HCl ER 28 mg/AChEI and Placebo/AChEI groups. Categories include Marked Improvement, Moderate Improvement, Minimal Improvement, No Change, Minimal Worsening, Moderate Worsening, and Marked Worsening. The chart visualizes the distribution of patient responses for each treatment.*

FDA Label Image

Namzaric 07

A line graph depicting SIB (Severe Impairment Battery) change from baseline over 6 months of drug treatment. The graph compares donepezil hydrochloride 10 mg/day, showing clinical improvement, with placebo, showing clinical decline. The vertical axis represents the mean change from baseline, and the horizontal axis represents months of drug treatment at 0, 3, and 6 months.*

FDA Label Image

Namzaric 08

A cumulative percentage curve graph comparing the percentage of patients over changes from baseline in SIB (Severe Impairment Battery) scores. The graph plots two groups: donepezil hydrochloride 10 mg/day (black circles) and placebo (open squares). The x-axis shows SIB change from baseline, and the y-axis shows the cumulative percentage of patients, illustrating differences in cognitive response between treatment and placebo.*

FDA Label Image

Namzaric 09

Line graph comparing ADCS-ADL mean change from baseline over 6 months of drug treatment between donepezil hydrochloride 10 mg/day and placebo. The vertical axis measures change with labels for clinical improvement and decline. The graph shows the donepezil group declines less than placebo over time.*

FDA Label Image

Namzaric 0a

A cumulative percentage of patients line graph comparing donepezil hydrochloride 10 mg/day to placebo. The x-axis shows ADCS-ADL Change from Baseline ranging from +20 to -20, and the y-axis shows the cumulative percentage of patients from 0% to 100%. The donepezil group shows a higher cumulative percentage of improvement compared to placebo.*

FDA Label Image

Namzaric 0b

Label for Namzaric extended-release capsules containing 7 mg memantine and 10 mg donepezil hydrochlorides per capsule. The package contains 30 capsules and is labeled by Allergan, Inc. It includes storage instructions and prescription-only status with NDC 0456-1207-30.*

FDA Label Image

Namzaric 0c

Namzaric 14 mg/10 mg extended-release capsules label showing product name, strengths, and active ingredients memantine and donepezil hydrochlorides. The label states it contains 30 capsules and is manufactured by Allergan, Inc. Additional storage, dosage, and safety information is also present.*

FDA Label Image

Namzaric 0d

Namzaric 21 mg/10 mg extended-release capsules label from Allergan, Inc. The label indicates 30 capsules per container, with active ingredients memantine and donepezil hydrochlorides. It includes storage instructions, dosage information, and manufacturer details. The packaging features a barcode and NDC 0456-1221-30.*

FDA Label Image

Namzaric 0e

Namzaric extended-release capsules containing memantine and donepezil hydrochlorides, 28 mg/10 mg per capsule, in a package of 30 capsules. The label is by Allergan, Inc. and includes storage instructions and dosage information, along with the NDC 0456-1228-30. The capsules are distributed by Allergan USA, Inc.*

FDA Label Image

Namzaric 0f

Namzaric titration pack packaging label for extended-release capsules containing memantine and donepezil hydrochlorides. The label details a four-week titration schedule with weekly dosages of 7 mg/10 mg, 14 mg/10 mg, 21 mg/10 mg, and 28 mg/10 mg. The pack is distributed by Allergan, Inc., includes capsules for initial four weeks of therapy, and features the National Drug Code (NDC) 0456-1229-29.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.